Allogene Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Allogene Therapeutics, Inc. (ALLO) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $108.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-12
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $36.31M, a 32.51% decline year-over-year.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $72.11M, a 27.64% increase year-over-year.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $61.99M, a 39.32% decline year-over-year.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $61.91M, a 43.61% decline year-over-year.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $234.20M, a 45.84% decline from fiscal 2024.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $432.46M, a 27.66% decline from fiscal 2023.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $597.81M, a 66.31% increase from fiscal 2022.
- Allogene Therapeutics, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $359.46M, a 50.65% decline from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month as first filed | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $36.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $108.43M 10-Q · filed 2026-08-12 | $170.42M derived: sum of 3 quarters · filed 2026-08-12 | $232.33M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $72.11M 10-Q · filed 2026-05-13 | $134.10M derived: sum of 2 quarters · filed 2026-05-13 | $196.02M derived: sum of 3 quarters · filed 2026-05-13 | $249.82M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $61.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $123.90M derived: sum of 2 quarters · filed 2026-03-12 | $177.70M derived: sum of 3 quarters · filed 2026-08-12 | $234.20M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $61.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $115.71M derived: sum of 2 quarters · filed 2026-08-12 | $172.21M 10-Q · filed 2025-11-06 | $274.38M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $53.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $110.30M 10-Q · filed 2026-08-12 | $212.47M derived: sum of 3 quarters · filed 2026-08-12 | $322.27M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $56.50M 10-Q · filed 2026-05-13 | $158.66M derived: sum of 2 quarters · filed 2026-05-13 | $268.47M derived: sum of 3 quarters · filed 2026-05-13 | $385.69M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $102.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $211.97M derived: sum of 2 quarters · filed 2026-03-12 | $329.19M derived: sum of 3 quarters · filed 2026-03-12 | $432.46M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $109.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $227.02M derived: sum of 2 quarters · filed 2025-11-06 | $330.29M 10-Q · filed 2025-11-06 | $466.64M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $117.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $220.49M 10-Q · filed 2025-08-13 | $356.84M derived: sum of 3 quarters · filed 2025-08-13 | $522.00M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $103.27M 10-Q · filed 2025-05-13 | $239.62M derived: sum of 2 quarters · filed 2025-05-13 | $404.77M derived: sum of 3 quarters · filed 2025-05-13 | $557.64M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $136.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $301.50M derived: sum of 2 quarters · filed 2025-03-13 | $454.37M derived: sum of 3 quarters · filed 2025-03-13 | $597.81M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $165.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $318.03M derived: sum of 2 quarters · filed 2024-11-07 | $461.47M 10-Q · filed 2024-11-07 | $560.55M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $152.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $296.31M 10-Q · filed 2024-08-07 | $395.39M derived: sum of 3 quarters · filed 2024-08-07 | $469.97M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $143.44M 10-Q · filed 2024-05-13 | $242.52M derived: sum of 2 quarters · filed 2024-05-13 | $317.10M derived: sum of 3 quarters · filed 2024-05-13 | $434.22M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $99.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $173.66M derived: sum of 2 quarters · filed 2024-03-14 | $290.78M derived: sum of 3 quarters · filed 2024-03-14 | $359.46M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $74.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $191.70M derived: sum of 2 quarters · filed 2023-11-02 | $260.38M 10-Q · filed 2023-11-02 | $342.92M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $117.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $185.80M 10-Q · filed 2023-08-02 | $268.34M derived: sum of 3 quarters · filed 2024-03-14 | $430.12M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $68.68M 10-Q · filed 2023-05-03 | $151.22M derived: sum of 2 quarters · filed 2024-03-14 | $313.00M derived: sum of 3 quarters · filed 2024-03-14 | $528.83M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $82.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $244.32M derived: sum of 2 quarters · filed 2024-03-14 | $460.14M derived: sum of 3 quarters · filed 2024-03-14 | $728.39M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $161.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $377.61M derived: sum of 2 quarters · filed 2022-11-02 | $645.85M 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | $215.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $484.07M 10-Q · filed 2022-08-09 | $484.08M 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | $268.25M 10-Q · filed 2022-05-04 | ||||
| 2020-09-30 | $150.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $251.52M derived: sum of 2 quarters · filed 2021-11-04 | $371.78M 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $101.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $221.63M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $120.26M 10-Q · filed 2021-05-05 | ||||
| 2019-09-30 | $158.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $355.76M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $197.41M 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |